Catalent's UpTempo℠ AAV Platform
CDMO Catalent’s UpTempo℠ adeno-associated viral (AAV) platform process accelerates time from gene to clinic.
Catalent’s UpTempo℠ adeno-associated viral (AAV) platform process accelerates the development and production of clinical material for gene therapy. With a simplified supply chain, increased development and manufacturing efficiencies, and standardized documentation, this scalable, cGMP-ready platform process can significantly reduce the time from gene to clinic. With viral vector and plasmid DNA development and clinical- and commercial-scale manufacturing facilities in its global network, Catalent offers horizontally integrated solutions to support advanced therapy programs.
Link: https://biologics.catalent.com/gene-therapy/process-development/aav-platform-process/
ASGCT 26th Annual Meeting
Visit booth 229 to meet with Catalent’s cell and gene therapy experts and learn more about the company’s integrated solutions for advanced therapeutics.
